Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen and Epigenomics Pen Licensing, OEM Deal for DNA Methylation Analysis

NEW YORK, May 3 (GenomeWeb News) - Qiagen and Epigenomics have signed a licensing and OEM deal to develop products to analyze DNA methylation, the companies said today.

 

Under the agreement, Venlo, the Netherlands-based Qiagen exclusively licensed Epigenomics' bisulfite DNA treatment technology as well as its MethyLight assay technology to develop products for research purposes. In exchange, Berlin-based Epigenomics will receive up-front technology access and licensing fees, as well as royalties on the sales of research products.

 

For diagnostic purposes, Qiagen will market and sell products containing the bisulfite technology for use with Epigenomics' technologies and products. Under an OEM agreement, Qiagen will also provide Epigenomics with kit components for molecular diagnostic products.

 

All products developed under the agreement will be co-branded, and the first products are expected in 2006.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.